G-BA, NICE recommend Teva's Cinqaero in severe eosinophilic asthma

U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Cinqaero reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to treat severe eosinophilic asthma. Teva said the decision was based on a dossier submitted to NICE under a single technology appraisal (STA).

The anticipated list price provided to NICE by Teva is £499.99 ($653.64) per 100 mg vial and £124.99 ($163.40) per 25 mg vial. The recommended dose is 3 mg/kg every four weeks. Teva has agreed provide Cinqaero at an undisclosed discount under a patient access scheme. ...